# A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis

> **NCT07663331** · PHASE4 · RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Adult Non-infectious Uveitis

## Interventions

- **DRUG:** TyboWe® Adalimumab Injection

## Key facts

- **NCT ID:** NCT07663331
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-14
- **Primary completion:** 2028-02
- **Final completion:** 2028-02
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663331, "A Multicenter, Open-label Study on the Efficacy and Safety of Tebiovio® (Adalimumab) in Treating Chinese Children With Severe Plaque Psoriasis". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07663331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*